The DOI matches its Crossref record; 53 of the 55 references it cites were found in a registry or an index.
Apolipoproteins as markers and managers of coronary risk
Abstract
Coronary artery disease (CAD) is a major cause of morbidity and mortality in Western communities. Reliable indices of coronary risk assessment and targets for drug treatment are important to the management of patients. Although plasma LDL cholesterol is well established as a predictor of CAD, it may not be the best circulatory marker. Results from recent epidemiological studies and statin trials suggest that apolipoprotein B-100 (apoB), with or without apoA-I, is superior to LDL cholesterol in predicting coronary events. Measurements of apolipoproteins are internationally standardized, automated, cost-effective and more convenient and precise than those for LDL cholesterol. ApoB may also be preferable to the measurement of non-HDL cholesterol. Measurement of apolipoproteins (apoB and possibly apoA-I) should be routinely added to the routine lipid profile (cholesterol, triglycerides and high-density lipoprotein cholesterol) to assess the atherogenic potential of lipid disorders. This is particularly relevant to dyslipidaemias characterized by an elevation in plasma triglycerides. Apolipoproteins, especially apoB, could also replace the standard "lipid profile" as a target for therapy in at-risk patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Apolipoproteins and the Apo B100/Apo A1 ratio have been investigated as biomarkers more senstive to identifying CVD risk than TC, TRG and LDL-C [9–11].”
In the citing paper
“which appear to be superior predictors of CVD risk compared to the SLP [4, 5, 9–14].”
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Yusuf, S., Hawken, S., Ôunpuu, S., Dans, T., Avezum, A., Lanas, F., McQueen, M., Budaj, A., Pais, P., Varigos, J., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17018-9 · Cited by 12,026
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Eckel, R. H., Alberti, K., Grundy, S. M., & Zimmet, P. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61794-3 · Cited by 6,317
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Grundy, S. M., Cleeman, J. I., Bairey Merz, C. N., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.07.001 · Cited by 1,550
Walldius, G., Jungner, I., Holme, I., AASTVEIT, A. H., Kolar, W., & Steiner, E. (2001) · The Lancet · doi:10.1016/s0140-6736(01)07098-2 · Cited by 1,227
Cited by
Sorted by citations
Indian Journal of Public Health Research & Development
Surwade, V. M., Ambedkar, B. S., Rohinee, & Delhi (2019) · Cited by 404
Ellagitannins, ellagic acid and vascular health
Larrosa, M., García‐Conesa, M., Espı́n, J. C., & Tomás-Barberán, F. A. (2010) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2010.09.005 · Cited by 390
Mechanisms of Action of trans Fatty Acids
Oteng, A., & Kersten, S. (2019) · Advances in Nutrition · doi:10.1093/advances/nmz125 · Cited by 331
Haney, E. M., Huffman, L. H., Bougatsos, C., Freeman, M., Steiner, R. D., & Nelson, H. D. (2007) · PEDIATRICS · doi:10.1542/peds.2006-1801 · Cited by 202
Ren, L., Yi, J., Li, W., Zheng, X., Liu, J., Wang, J., & Du, G. (2019) · Cancer Medicine · doi:10.1002/cam4.2587 · Cited by 145
Metadata
- Authors
- Chan, D. C.
- Affiliations
- The University of Western Australia (AU)
- Corresponding author
- Chan, D.C.
- ORCID
- Chan, D.C.
- Venue
- QJM
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-02-27
- Volume
- 99
- Issue
- 5
- Pages
- 277-287
- ISSN
- 0033-5622 (ISSN-L)
- 1460-2725
- 1460-2393
- OpenAlex
- W2161147110
- Cited by
- 117
- References
- 55
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 4 · 2023: 6 · 2022: 6 · 2021: 2 · 2020: 5 · 2019: 7 · 2018: 4 · 2017: 5 · 2016: 8 · 2015: 2 · 2014: 9 · 2013: 3 · 2012: 4
- FWCI
- 1.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- QJM (publishedVersion)
- PubMed (publishedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- Funders
- National Heart Foundation of Australia
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- apolipoprotein B-100, apolipoprotein A-I, coronary artery disease, coronary risk assessment, LDL cholesterol, non-HDL cholesterol, dyslipidemia, triglyceride elevation, lipid profile, atherogenic lipoproteins
- MeSH terms
- Anticholesteremic Agents, Apolipoproteins, Apolipoproteins B, Cholesterol, Coronary Artery Disease, Female, Humans, Cholesterol, HDL, Cholesterol, LDL, Male, Biomarkers, Apolipoprotein A-I, Risk Assessment, Apolipoprotein B-100
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
